早期使用二甲双胍可降低长新冠或死亡风险53%
Metformin may lower risk of long COVID or death by 53% when prescribed early
一项研究发现,美国COVID-19患者在感染后六天内使用二甲双胍治疗,比对照组降低了53%的长新冠或死亡风险。研究使用电子健康记录进行目标试验模拟,结果显示二甲双胍组的长新冠或死亡发生率比对照组低4.5个百分点。
研究发现早期使用二甲双胍可降低长新冠或死亡风险53%,为治疗长新冠提供新线索。
Long COVID—or new-onset symptoms or worsening health conditions after SARS-CoV-2 infection—can lower quality of life. Finding a way to prevent it would be a welcome relief for those worried about the long-term effects of the viral infection.
A study published in the Journal of Medical Virology finds that U.S. COVID-19 patients prescribed metformin, a medication that treats prediabetes and type 2 diabetes, within six days of COVID-19 infection were less likely to develop long COVID or die.
"Metformin prescription within the week following documented SARS-CoV-2 infection was associated with a 53% reduction in LC/D [long COVID or death] over six months in this primarily omicron-infected sample," wrote the authors, led by researchers from the University of Minnesota Medical School.
Findings could help guide treatment recommendations
Using electronic health records, the scientists conducted a target trial emulation in COVID-infected participants. They compared 248 people who received a new metformin prescription within six days of diagnosis with the same number of controls prescribed the experimental treatments fluvoxamine, fluticasone, ivermectin or montelukast within that same time frame.
Half of the metformin cohort and more than half (52%) of the control group were infected with the omicron SARS-CoV-2 variant.
Overall, the weighted incidence of long COVID or death in patients receiving metformin or control treatment within six days of diagnosis was 6.3%: 4.0% in the metformin cohort and 8.5% in controls (absolute risk reduction, 4.5 percentage points for metformin).
"These results are also consistent with a recent sequential target trial analysis in the United Kingdom that assessed metformin started within 90 days of infection, HR [hazard ratio] 0.36," the authors wrote. "The replication of results in clinical trials is important for informing treatment guidelines."
More information
Carolyn T. Bramante et al., Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study, Journal of Medical Virology (2026). DOI: 10.1002/jmv.71190
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Metformin may lower risk of long COVID or death by 53% when prescribed early (2026, November 6) retrieved 6 November 2026 from https://medicalxpress.com/news/2026-11-metformin-covid-death-early.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com